Vera Therapeutics reports Q1 net loss of $30.1M; atacicept Phase 3 to start Q2 2023

Vera Therapeutics, Inc.

2023-Q1 EPS reported -$0.80

Net loss of $30.1M ($0.80 per diluted share) vs $17.1M ($0.71) in Q1 2022.
Cash, cash equivalents, and marketable securities of $197.2M as of March 31, 2023; expected to fund operations to early 2026.
36-week data from Phase 2b ORIGIN trial of atacicept in IgAN selected as late-breaking presentation at ERA Congress 2023.
Plan to initiate pivotal Phase 3 trial of atacicept in IgAN in Q2 2023.
Appointed Kerry Cooper, M.D., as Senior Vice President of Medical Affairs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vera Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income net loss of $30.1 million, EPS net loss per diluted share of $0.80.

Period: the first quarter ended March 31, 2023
Net income: net loss of $30.1 million
EPS: net loss per diluted share of $0.80
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2023, the company reported a net loss of $30.1 million, or a net loss per diluted share of $0.80

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.